DR. DAVID WESLEY VAUGHN, M.D.
Medical Practice at Redgate Dr, Silver Spring, MD
License number
Maryland MD00026233
Category
Medical Practice
Type
Pediatrics
License number
Maryland 01034261A
Category
Medical Practice
Type
Pediatrics
Address
Address
15108 Redgate Dr, Silver Spring, MD 20905
Phone
(301) 879-2388
Personal information
See more information about DAVID WESLEY VAUGHN at radaris.comName
Address
Phone
57 Whitecavage Ct, Conowingo, MD 21918
5 Ramsgate Ct, Halethorpe, MD 21227
6657 Dovecote Dr, Columbia, MD 21044
810 Pecan Ct, Bel Air, MD 21014
2288 Canteen Cir, Odenton, MD 21113
Professional information
Dr. David W Vaughn, Silver Spring MD - MD (Doctor of Medicine)
Specialties:
Pediatrics
Address:
15108 Redgate Dr, Silver Spring 20905
(301) 879-2388 (Phone)
(301) 879-2388 (Phone)
Certifications:
Pediatrics, 1987
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Saint Louis University / School of Medicine
Graduated: 1983
Ind U-Riley Chldns Hosp
Saint Louis University / School of Medicine
Graduated: 1983
Ind U-Riley Chldns Hosp
Attenuated Dengue-2 Virus Vaccine
US Patent:
6511667, Jan 28, 2003
Filed:
Mar 24, 2000
Appl. No.:
09/534725
Inventors:
Kenneth H. Eckels - Rockville MD
Joseph R. Putnak - Silver Spring MD
Doria R. Dubois - Wheaton MD
Bruce L. Innis - Haverford PA
Charles H. Hoke - Columbia MD
David Vaughn - Silver Spring MD
Niranian Kanesa-thasan - Rockville MD
Joseph R. Putnak - Silver Spring MD
Doria R. Dubois - Wheaton MD
Bruce L. Innis - Haverford PA
Charles H. Hoke - Columbia MD
David Vaughn - Silver Spring MD
Niranian Kanesa-thasan - Rockville MD
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K 39193
US Classification:
4242181, 435237
Abstract:
The present invention provides vaccine compositions of attenuated dengue-2 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-2 virus by administration of attenuated dengue-2 virus.
Attenuated Dengue-3 Virus Vaccine
US Patent:
6528065, Mar 4, 2003
Filed:
Mar 24, 2000
Appl. No.:
09/535684
Inventors:
Kenneth H. Eckels - Rockville MD
Joseph R. Putnak - Silver Spring MD
Doria R. Dubois - Wheaton MD
Bruce L. Innis - Hayerford PA
Charles H. Hoke - Columbia MD
David Vaughn - Silver Spring MD
Joseph R. Putnak - Silver Spring MD
Doria R. Dubois - Wheaton MD
Bruce L. Innis - Hayerford PA
Charles H. Hoke - Columbia MD
David Vaughn - Silver Spring MD
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K 3912
US Classification:
4242181, 4242041, 4242781
Abstract:
The present invention provides immunogenic compositions of attenuated dengue-1 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-1 virus by administration of attenuated dengue-1 virus.
Attenuated Dengue-4 Virus Vaccine
US Patent:
6537557, Mar 25, 2003
Filed:
Mar 24, 2000
Appl. No.:
09/534726
Inventors:
Kenneth H. Eckels - Rockville MD
Joseph R. Putnak - Silver Spring MD
Doria R. Dubois - Wheaton MD
Bruce L. Innis - Haverford PA
Charles H. Hoke - Columbia MD
David Vaughn - Silver Spring MD
Joseph R. Putnak - Silver Spring MD
Doria R. Dubois - Wheaton MD
Bruce L. Innis - Haverford PA
Charles H. Hoke - Columbia MD
David Vaughn - Silver Spring MD
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K 39193
US Classification:
4242181, 435236
Abstract:
The present invention provides vaccine compositions of attenuated dengue-4 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-4 virus by administration of attenuated dengue-4 virus.